Based on the Anika Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Anika Therapeutics Inc is USD 27.33 over the next 12 months. Anika Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Anika Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Anika Therapeutics Inc’s stock price was USD 13.72. Anika Therapeutics Inc’s stock price has changed by +4.41% over the past week, -13.76% over the past month and -46.22% over the last year.
No recent analyst target price found for Anika Therapeutics Inc
No recent average analyst rating found for Anika Therapeutics Inc
Company Overview Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Read Less
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Eu...Read More
Frequently Asked Questions About Anika Therapeutics Inc (ANIK) Stock
Based on ratings from 1 analysts Anika Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANIK's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ANIK is USD 27.33 over the next 12 months. The maximum analyst target price is USD 37 while the minimum anlayst target price is USD 20.
ANIK stock's Price/Earning ratio is 78.21.
Our analysis grades ANIK stock's Price / Earning ratio at F. This means that ANIK stock's Price/Earning ratio is above 82% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ANIK may be a overvalued for its sector.
The last closing price of ANIK's stock was USD 13.72.
The most recent market capitalization for ANIK is USD 0.20B.
Based on targets from 1 analysts, the average taret price for ANIK is projected at USD 27.33 over the next 12 months.
This means that ANIK's stock price may go up by +99.22% over the next 12 months.
We can't find any ETFs which contains Anika Therapeutics Inc's stock.
As per our most recent records Anika Therapeutics Inc has 288 Employees.
Anika Therapeutics Inc's registered address is 32 Wiggins Avenue, Bedford, MA, United States, 01730.
You can get more information about it from Anika Therapeutics Inc's website at https://www.anika.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Anika Therapeutics Inc (ANIK) Stock
Based on ratings from 1 analysts Anika Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANIK's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ANIK is USD 27.33 over the next 12 months. The maximum analyst target price is USD 37 while the minimum anlayst target price is USD 20.
ANIK stock's Price/Earning ratio is 78.21.
Our analysis grades ANIK stock's Price / Earning ratio at F. This means that ANIK stock's Price/Earning ratio is above 82% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ANIK may be a overvalued for its sector.
The last closing price of ANIK's stock was USD 13.72.
The most recent market capitalization for ANIK is USD 0.20B.
Based on targets from 1 analysts, the average taret price for ANIK is projected at USD 27.33 over the next 12 months.
This means that ANIK's stock price may go up by +99.22% over the next 12 months.
We can't find any ETFs which contains Anika Therapeutics Inc's stock.
As per our most recent records Anika Therapeutics Inc has 288 Employees.
Anika Therapeutics Inc's registered address is 32 Wiggins Avenue, Bedford, MA, United States, 01730.
You can get more information about it from Anika Therapeutics Inc's website at https://www.anika.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANIK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
